Ethyl Pyruvate Inhibits Influenza Viral Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for influenza, including vaccination and antiviral medications, have limited efficacy due to the high mutation rate of influenza viruses and the emergence of resistant strains, and there is a need for alternative therapies that can effectively inhibit viral binding and replication without significant side effects.
Innovation Solution
Ethyl pyruvate is used to competitively inhibit the binding of influenza viruses to sialic acid-containing sugar chains and inhibit viral neuraminidases, while also having antioxidant, anti-inflammatory, and antibacterial properties, thereby preventing viral replication and reducing inflammation and tissue damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral medications are used to treat influenza, then viral replication is inhibited to some extent, but the viruses develop resistance and efficacy is limited
Solution Approach 1:
The patent introduces sialic acid analogs as intermediary compounds that interfere with the viral binding process. These analogs compete with host cell sialic acid receptors for viral hemagglutinin binding, thereby preventing viral entry and replication without directly inhibiting viral enzymes, which reduces the development of resistance.
Solution Approach 2:
The patent modifies the chemical structure of sialic acid by changing specific parameters (acetyl groups at positions 4, 7, 8, and 9) to create analogs with altered binding properties. This structural parameter change allows the analogs to bind to viral hemagglutinin with higher affinity than natural sialic acid, effectively blocking viral replication while avoiding resistance development.
2Reliability
If vaccination is used to prevent influenza, then immune response is stimulated, but the high mutation rate of influenza viruses reduces vaccine efficacy over time
Solution Approach 1:
The patent employs sialic acid analogs as preliminary protective agents that preemptively block viral binding before infection occurs. By continuously occupying the binding interface between viral hemagglutinin and host cell receptors, these analogs prevent viral entry regardless of viral strain variations, providing broad-spectrum protection without requiring annual vaccine updates.
3Productivity
If existing antiviral treatments are used, then viral replication is suppressed, but side effects and toxicity occur
Solution Approach 1:
The sialic acid analogs utilize the host cell's own sialic acid receptors and metabolic pathways to achieve viral inhibition. The analogs are metabolized by host cell enzymes and leverage the natural binding interface between viruses and host cells, thereby avoiding the need for foreign chemical agents that could cause toxicity while maintaining effective viral replication suppression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ethyl pyruvate effectively prevents viral binding, inhibits replication, reduces inflammation, and protects tissues without adverse side effects, making it a versatile tool for treating and preventing influenza infections.
Implementation Method 1
Ethyl pyruvate is used to competitively inhibit the binding of influenza viruses to sialic acid-containing sugar chains
Implementation Method 2
inhibit viral neuraminidases, while also having antioxidant, anti-inflammatory, and antibacterial properties
Implementation Method 3
having antioxidant, anti-inflammatory, and antibacterial properties
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a compound according to the general formula (I) for use in the treatment or prophylaxis of a disease associated with an interaction of a receptor comprising a sialic acid-containing sugar chain with a cognate binding element, wherein the interaction takes place at the surface of a cell, or for inducing regression or elimination or inhibition of the progression of at least one sign or symptom of said disease, in a subject. Further envisaged is a corresponding method of treatment as well as a pharmaceutical composition. In a preferred embodiment, the disease is virus infection, in particular an Influenza infection.